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SUMMARY
Ubiquitin-mediated inactivation of caspases has long been postulated to contribute to the
regulation of apoptosis. However, detailed mechanisms and functional consequences of caspase
ubiquitylation have not been demonstrated. Here we show that the Drosophila Inhibitor of
Apoptosis 1, DIAP1, blocks effector caspases by targeting them for polyubiquitylation and
nonproteasomal inactivation. We demonstrate that the conjugation of ubiquitin to drICE
suppresses its catalytic potential in cleaving caspase substrates. Our data suggest that ubiquitin
conjugation sterically interferes with substrate entry and reduces the caspase’s proteolytic velocity.
Disruption of drICE ubiquitylation, either by mutation of DIAP1’s E3 activity or drICE’s
ubiquitin-acceptor lysines, abrogates DIAP1’s ability to neutralize drICE and suppress apoptosis
in vivo. We also show that DIAP1 rests in an “inactive” conformation that requires caspase-
mediated cleavage to subsequently ubiquitylate caspases. Taken together, our findings
demonstrate that effector caspases regulate their own inhibition through a negative feedback
mechanism involving DIAP1 “activation” and nondegradative polyubiquitylation.
INTRODUCTION
The covalent attachment of ubiquitin (Ub) to target proteins critically influences cellular
processes such as NF-κB signaling, DNA repair, and cell survival (Haglund and Dikic,
2005). At the molecular level, Ub conjugation can alter a protein’s conformation and/or
binding properties, changing its activity, localization, or half-life.
Ub chains are assembled in a stepwise process that involves Ub-activating enzymes (E1),
Ub-conjugating enzymes (E2), and Ub-protein ligases (E3) (Hershko et al., 2000). E3s
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confer substrate specificity and enable the transfer of Ub from an E2 to lysine (K) residues
on target substrates (Hershko et al., 2000). Ub is conjugated either as a single moiety (mono-
Ub) or as poly-Ub chains (Haglund and Dikic, 2005) that are generally linked through K48
or K63 of Ub. The different types of poly-Ub chains have diverse effects, K48-linked
modifications promoting degradation through recognition by the 26S proteasome and mono-
Ub, as well as K63-linkages, contributing to a variety of nondegradative signaling processes
(Hoeller et al., 2006).
A large body of evidence demonstrates the involvement of Ub conjugation in apoptosis
regulation (Hoeller et al., 2006; Vaux and Silke, 2005). Protein levels of many key
regulatory molecules, including p53 (Brooks and Gu, 2006), IAPs (Vaux and Silke, 2005),
Bim (Ley et al., 2003), Mcl1 (Zhong et al., 2005), and c-FLIP (Chang et al., 2006), are
controlled by Ub-dependent degradation. With regards to caspase regulation, the picture is
less clear. Caspases are regulated by members of the IAP protein family, and IAP-mediated
mono- and polyubiquitylation of caspases has been reported for a number of IAPs and
caspases (Vaux and Silke, 2005). However, biochemical insights into the actual molecular
and functional consequences of caspase ubiquitylation are missing.
Caspases are expressed as zymogens consisting of a prodomain and a large (p20) and small
subunit (p10) (Riedl and Shi, 2004). Proteolytic activation is initiated by the activation of
initiator caspases that cleave and activate downstream effector caspases. In a positive
feedback loop, effector caspases activate other caspases and amplify the proteolytic activity
(Berger et al., 2006; Denault et al., 2006). During activation, their prodomains are removed
by cleavage. The position of the initial cleavage differs among caspases; while caspase-3 is
first cleaved at the interdomain-linker position, caspase-7 and the Drosophila effector
caspases drICE and DCP-1 are first processed at the prodomain site generating ΔN-caspases
(Denault and Salvesen, 2003; Riedl and Shi, 2004; Tenev et al., 2005).
Certain IAPs inhibit caspases and can function as a last line of defense against caspase-
mediated damage. IAPs are classified by the presence of the Baculovirus IAP repeat (BIR)
domain (Vaux and Silke, 2005). Drosophila DIAP1 and mammalian XIAP bind to both
initiator and effector caspases via their BIR domains and adjacent flanking regions. In most
cases, binding to BIR domains is mediated by an IAP-binding motif (IBM) present in IAP
antagonists (Shi, 2002), such as Reaper (Rpr), or caspases such as drICE, DCP-1, and
caspase-7 and -9 (Denault and Salvesen, 2003; Srinivasula et al., 2001; Tenev et al., 2005).
Generally, IBMs carry an NH2-terminal Alanine (A) residue at position 1 that anchors this
motif into the BIR domain (Wu et al., 2001). Upon processing, the IBMs of drICE and
DCP-1 become exposed, allowing their detection by IAPs (Tenev et al., 2005). Although
required for DIAP1 binding, fully active effector caspases associate with DIAP1 through a
bimodular interaction involving both the IBM and the catalytic pocket.
DIAP1 reportedly inhibits caspases in vitro (Kaiser et al., 1998; Yan et al., 2004). However,
physical interaction alone is insufficient to maintain cell viability in vivo. Mutations of
DIAP1’s RING-finger domain, which abrogate its E3 activity but not caspase binding, cause
a loss-of-function phenotype (Lisi et al., 2000; Wilson et al., 2002). Following binding, the
RING is required to ubiquitylate and inactivate Drosophila initiator caspase DRONC (Chai
et al., 2003; Wilson et al., 2002). Moreover, effector caspases are also neutralized in a
RING-dependent manner (this study and Herman-Bachinsky et al. [2007] and Lisi et al.
[2000]). However, while necessary, the RING is not sufficient to inhibit caspases as
recruitment of the NH2-end-rule Ub-associated machinery is also required (Ditzel et al.,
2003). Effector caspases cleave DIAP1 at its NH2 terminus, which exposes a binding motif
for UBR-domain-bearing class of NH2-end-rule E3s (UBR-E3s) (Ditzel et al., 2003;
Herman-Bachinsky et al., 2007; Yan et al., 2004; Yokokura et al., 2004). Although UBR
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recruitment and DIAP1’s RING are required for DIAP1’s antiapoptotic activity (Ditzel et
al., 2003; Muro et al., 2005), the mechanism and consequence of caspase ubiquitylation
remain unclear. IAP-mediated ubiquitylation of caspases is not restricted to Drosophila, as
mammalian XIAP reportedly polyubiquitylates caspase-3, targeting it for degradation
(Suzuki et al., 2001). Moreover, cIAP2 monoubiquitylates caspase-3 and -7 in vitro (Huang
et al., 2000). However, the relevance of these observations remains unresolved, since XIAP
knockout animals display limited cell death phenotypes (Harlin et al., 2001), and the
functional outcome of caspase monoubiquitylation has not been determined. All in all, there
are numerous reports that link Ub conjugation to caspase regulation; however, no clear
picture has emerged that might help to explain how Ub conjugation inactivates these
proteases.
Here we have addressed the molecular mechanism and functional consequence of DIAP1-
mediated ubiquitylation of effector caspases. Surprisingly, we found that full-length DIAP1
rests in an “inactive” configuration that precludes caspase binding. Following caspase-
mediated cleavage, DIAP1 becomes fully competent to bind caspases and function as an E3.
DIAP1-mediated drICE ubiquitylation suppresses its catalytic ability to cleave the substrates
PARP and DEVD-AMC. Disruption of drICE ubiquitylation, either by loss of DIAP1’s E3
activity or generation of a nonubiquitylatable form of drICE, renders it resistant to DIAP1-
mediated inactivation. Our data provide a likely explanation of how cells maintain buffered
levels of active caspases without losing cell viability. It appears that caspases, through
cleaving DIAP1, initiate their own inhibition. Such a scenario would result in a buffered
“oscillating cycle” of caspase activity that would establish a continuous presence of
sublethal levels of active caspases.
RESULTS
Alteration of DIAP1’s Physical Properties through NH2-Terminal Cleavage
To investigate the biochemical basis for caspase inhibition by cleaved DIAP1
(DIAP121–438), we performed binding assays with DRONC, drICE, DCP-1, and Rpr (Figure
1). Nontagged full-length or truncation mutants of DIAP1 were expressed along with V5-
tagged caspases or IAP antagonists. α-V5 antibodies were used to purify caspases and IAP
antagonist from cellular extracts, and the presence of copurified DIAP1 was detected using
an α-DIAP1 antibody. Mammalian cells were chosen to avoid potential interference by
endogenous DIAP1 and because wild-type DIAP1 remains largely unprocessed in 293 cells
(Figure 1B). Interestingly, DIAP121–438 interacted with DRONC, drICE, and DCP-1 far
better than full-length DIAP1, which bound caspases only weakly (Figures 1B–1D).
Notably, drICE enriched the small amount of cleaved DIAP1 over its unprocessed form
(Figure 1C, lane 1). Under these conditions, drICE barely bound to noncleaved DIAP1 or
DIAP1D20A, which remains full-length due to a mutation in the caspase cleavage site.
Removal of DIAP1’s N peptide, but not generation of a particular neo-NH2 terminus, was
required for caspase binding. Both, N- and M-DIAP121–438, in which N21 was replaced by
M21, and therefore does not bind NH2-end-rule E3s (see below), associated with caspases
equally well (Figures 1B–1D). As expected, Rpr equally bound to DIAP1wt, DIAP1D20A,
and DIAP121–438 (Figure 1E), a finding that is consistent with its epistatic position upstream
of DIAP1 (Wang et al., 1999).
Since DIAP1 bears Alanine at the second position (A2), it was previously suggested that A2
mediates intramolecular binding to the BIR domains (Yan et al., 2004), thereby locking
DIAP1 into a “closed” conformation that prevents caspase binding. However, DIAP1A2G, in
which A2 was replaced by glycine (G) that does not allow BIR binding (Wu et al., 2001),
also failed to interact with DCP-1 (see Figure S1 available online). This indicates that A2
does not contribute to the “closed” configuration of DIAP1.
Ditzel et al. Page 3
Mol Cell. Author manuscript; available in PMC 2009 November 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The Neo-NH2 Terminus of Cleaved DIAP1 Binds to the UBR Box Motif of E3 Ligases
DIAP1 cleavage exposes a previously hidden “docking” site for E3 ligases with a UBR
domain. UBR domains generally recognize target proteins via NH2-terminal residues
(Tasaki et al., 2005). For N21 of DIAP121–438 to bind to UBR domains, it must be converted
to Aspartate (D) by NH2-terminal amidohydrolases and conjugated with Arginine (R) to
create the mature NH2-terminal RD21 motif (Figure 2A; Varshavsky et al., 2000). Because
of their size (200 kDa for UBR1), we used isolated UBR domains to determine which of the
six Drosophila UBR-bearing E3s bind DIAP1. The UBR domains of UBR1, -3, -5, -6, and
-7 bound to DIAP121–438, whereas UBR4 showed no detectable interaction (Figure 2B). The
binding between DIAP121–438 and UBR1 was strictly dependent on a compatible NH2-
terminal. M-DIAP121–438 in which N21 was replaced by methionine (M), an Aa that does
not allow UBR binding (Tasaki et al., 2005), failed to copurify with UBR1 (Figure 2C).
Under the same conditions, UBR1 readily bound to both N-DIAP121–438 and RD-
DIAP121–438, which mimics a fully matured NH2-terminal UBR-binding motif. The
observation that several UBRs bind to DIAP121–438 suggests significant redundancy among
UBRs, a view that is supported by knockout studies in mice (Kwon et al., 2003).
DIAP121–438 Targets Effector Caspases for Polyubiquitylation in a RING and UBR Binding-
Dependent Manner
Next, we examined the ability of DIAP1 to promote caspase ubiquitylation (Figures 2D–2F).
Nontagged DIAP121–438 was coexpressed with V5-tagged DCP-1 or drICE and His-tagged
Ub. Ubiquitylated proteins were affinity purified under denaturing conditions using nickel
columns, and the presence of ubiquitylated caspases was assessed by immunoblotting the
eluate with α-V5 antibodies. Under these conditions, DIAP121–438 readily ubiquitylated
DCP-1 and drICE (Figures 2D–2F). In contrast, M-DIAP121–438 and the DIAP1 RING
mutant DIAP121–438/C406Y were impaired in their ability to ubiquitylate DCP-1 and drICE
(Figures 2D–2F). Mutation of drICE’s IBM (ALG- to LG-drICE), which weakens DIAP1
binding (Tenev et al., 2005), resulted in less efficient ubiquitylation (Figure 2F). Consistent
with the notion that DIAP1 ubiquitylates drICE, we found that, in healthy S2 cells,
endogenous drICE was ubiquitylated in a DIAP1-dependent manner (Figure 2G). This is
evident because exposure to UV or treatment with a small pharmacological inhibitor of IAPs
that mimics SMAC caused DIAP1 depletion and resulted in reduced levels of ubiquitylated
drICE (Figure 2G; M.B. and P.M., unpublished data). These results indicate that DIAP1
ubiquitylates effector caspases and that both exposure of a UBR-binding motif and the
presence of a functional RING finger are required for maximal ubiquitylation of effector
caspases.
Exposure of an UBR-Binding Motif and DIAP1’s Own RING Finger Are Both Required for
DIAP1’s Antiapoptotic Activity In Vivo
To address the contribution of DIAP1’s NH2-terminal UBR-binding domain for its
antiapoptotic activity in vivo, we generated a number of transgenic fly lines expressing
various DIAP1 mutants under the control of the tubulin promoter. We used the Ub-protein
reference technique (Varshavsky, 2000) (Figure 3A) and quantitative, infrared fluorescence-
based measurement (Odyssey, LI-COR) of V5-DHFR/Ub to select lines with similar
transgene expression levels (Figure 3B).
Eye-specific (GMR) expression of Rpr causes apoptosis in the developing retina that results
in a small-eye phenotype (White et al., 1996) (Figure 3C). Tubulin-driven expression of
DIAP1wt and N-DIAP121–438 suppressed this eye phenotype (Figures 3D and 3F). In
contrast, DIAP1D20A and M-DIAP121–438 failed to provide any significant protection
(Figures 3E and 3G), despite DIAP1D20A being expressed 1.5-fold above the levels of N-
DIAP121–438 and 2.2-fold above that of DIAP1wt (Figure 3B). Notably, all DIAP1 variants
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showed comparable binding to Rpr (Figure 1E; Zachariou et al., 2003). Interestingly, N-
DIAP121–438/C406Y, which lacks a functional RING, failed to inhibit Rpr-mediated cell
death (Figure 3J). Thus, both exposure of an UBR-binding motif and the presence of a
functional RING are essential for DIAP1’s antiapoptotic activity. Either mechanism alone
fails to protect from Rpr killing.
DIAP1-Mediated Inhibition of drICE Depends on Binding- and Ub-Dependent Activities
To quantitate DIAP1’s ability to suppress caspases, we used the fluorometric caspase
substrate Ac-DEVD-AMC in a cell-based assay. In Drosophila tissue culture cells (S2), like
in the developing eye, induced expression of Rpr triggers apoptosis that is predominantly
mediated by drICE (Fraser et al., 1997; Leulier et al., 2006; Xu et al., 2006) and is
efficiently blocked by coexpression of DIAP1wt. Notably, in this system, DIAP1 acts
through inhibiting effector caspases (Figure S2; Tenev et al., 2007; and data not shown).
DIAP1 efficiently suppressed DEVDase activity induced by Rpr expression (Figure 4A).
Cleavable and E3-proficient DIAP1wt and N-DIAP121–438 were most effective at
suppressing DEVDase activity. In contrast, DIAP1D20A, M-DIAP121–438, or the E3 mutants
DIAP121–438/C406Y, DIAP121–438/CΔ6, and DIAP121–438/F437A were strongly impaired in
suppressing DEVDase activity. DIAP121–438/CΔ6 and DIAP121–438/F437A are defective in
their E3 activity because they either lack the last 6 Aa (CΔ6) or carry a mutation in F437
essential for E3 activity (Silke et al., 2005). Consistently, DIAP121–438/CΔ6,
DIAP121–438/F437A, and DIAP121–438/C406Y failed to polyubiquitylate drICE (Figures 2D,
2F, and 4B). Importantly, these E3 mutants bound to drICE as efficiently as DIAP121–438
(data not shown), indicating that DIAP1’s E3 activity is required to suppress caspase
activity. The small, but measurable, residual ability of these mutants to suppress DEVDase
activity (Figures 4A and 4C) is due to mere physical interaction (Yan et al., 2004).
Therefore, DIAP1-mediated regulation of effector caspases results from a binding-and Ub-
dependent activity.
drICE is activated through cleavage at D230 (Figure 4C), which occurs upon apoptotic insult
or induced expression of drICE. A short 6 hr pulse of drICE induction resulted in its
proteolytic activation, as measured by the appearance of the p10 in immunoblot analysis and
DEVDase activity (Figure 4C). Of note, under these conditions, no apoptosis or
morphological changes are detectable, and the majority of drICE is activated by
autocleavage. Expression of catalytically inactive drICEC>A did not result in its cleavage
(data not shown). The observation that effector caspases can feed back on themselves is
consistent with activation of caspase-7, whose processing is by and large mediated by
mature caspase-7 (Berger et al., 2006; Denault et al., 2006). When drICEwt was coexpressed
with N-DIAP121–438, processed drICE was undetectable, and very little DEVDase activity
was measured (Figure 4C). In contrast, processed drICE and DEVDase activity were
detectable in the presence of N-DIAP121–438/C406Y, N-DIAP121–438/CΔ6, N-
DIAP121–438/F437A, or M-DIAP121–438 (Figure 4C and 4D). Thus, DIAP1 that fails to
ubiquitylate drICE efficiently is impaired in suppressing it.
DIAP1 Targets drICE for Polyubiquitylation and Inactivation through a Nondegradative
Mechanism
drICE may be inactivated through Ub-mediated proteasomal degradation. According to such
a scenario, proteasome inhibition should result in accumulation of ubiquitylated drICE, and
appearance of its small subunit despite the presence of DIAP1. However, Lactacystin
treatment did not cause accumulation of ubiquitylated drICE when compared to untreated
controls (Figure 5A). Moreover, exposure to cycloheximide and/or MG132, another
proteasome inhibitor, did not change the ubiquitylation pattern of drICE (Figure S3) or
restore the appearance of the p10 (Figure 5B). Further, clonal overexpression of DIAP1 in
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the developing eye did not result in drICE depletion (Figure 5C), indicating that DIAP1 does
not target drICE for proteasomal destruction. Moreover, in vitro ubiquitylation assays
suggest that DIAP1 is not only capable, but better at promoting nondegradative K63-linked
polyUB chains than degradative K48-linked chains (Herman-Bachinsky et al., 2007).
Although DIAP1 can promote K48- and K63-linked polyUB chains on drICE, DIAP1 makes
longer K63-Ub chains (Figure S4, compare lane 2 with 4 and 5).
Consistent with the notion that DIAP1 blocks drICE processing, we found that drICE
remained predominantly unprocessed (92%) when DIAP1 was coexpressed (Figure 5D).
However, in the absence of DIAP1 most drICE was cleaved, with only 35% of total drICE
remaining full-length. drICE was also activated (processed) in the presence of
DIAP121–438/CΔ6 and DIAP121–438/C406Y. Since cleavage of drICE requires an input from
active drICE, it appears that DIAP1-mediated ubiquitylation of drICE results in its
inactivation. Similarly, z-VAD-fmk also suppressed the appearance of the small subunit of
drICE (Figure 5B).
Ub Conjugation Inhibits Active drICE
To test whether ubiquitylation directly affects the proteolytic activity of drICE, we devised
an in vitro ubiquitylation assay followed by a cleavage reaction using PARP as the caspase
substrate (Figures 6A and 6B). Several slow migrating drICE species were detected when
recombinant, active drICE was incubated with E1, E2/UbcD1, Ub, and DIAP1, which were
not detected in the presence of the E3 mutant DIAP1F437A—indicating that they are
ubiquitylated products (Figure 6A). The mixture containing either ubiquitylated or
nonubiquitylated drICE was subsequently incubated with PARP (Figures 6A and 6B) or
DEVD-AMC (Figure 6C). While recombinant drICE cleaved 89% of PARP, the mixture
containing ubiquitylated drICE was significantly less active in processing PARP, with only
42% of PARP being cleaved (Figure 6A). In contrast, nonubiquitylated drICE incubated
with E3-defective DIAP1F437A cleaved PARP as efficiently as controls (80% cleaved)
(Figure 6A). Moreover, time course analysis and concentration-dependent cleavage assays
with PARP and DEVD-AMC further corroborate the notion that nonubiquitylated and
ubiquitylated drICE significantly differ in their KM and Vmax (Figures 6B–6D). Since
DIAP1 and DIAP1F437A bind to drICE equally well, but DIAP1F437A fails to ubiquitylate
drICE, this result indicates that ubiquitylation significantly reduces the catalytic potential of
drICE. This suggests that DIAP1-mediated drICE ubiquitylation leads to its nondegradative
suppression, possibly through steric interference with substrate entry (see below and Figure
S5). Since ubiquitylation affects KM and Vmax, it seems possible that it functions as a mixed
inhibitor, whereby Ub sterically occludes substrate entry and causes a conformational
change of the caspase reducing its catalytic processivity.
Nonubiquitylatable drICE Is Refractory to DIAP1-Mediated Inhibition
If ubiquitylation of drICE results in inactivation, then drICE mutants that cannot be
ubiquitylated should be resistant to DIAP1-mediated inhibition. To test this, we generated a
nonubiquitylatable mutant of drICE. Structural prediction of drICE revealed nine surface
exposed K residues (Figures 7A–7E). In vitro ubiquitylation assays with a Ub mutant that
lacks all seven lysine residues (K0) and therefore can only form mono-Ub conjugates
indicated that DIAP1 can ubiquitylate drICE at five K residues simultaneously (Figure
S6A). Sequential, additive rounds of mutagenesis generated a series of K>R mutants (Figure
7F) and revealed that mutation of all nine K residues in the p20 (drICE9K>R) was required to
abrogate drICE ubiquitylation (Figure 7G). Under the same conditions, drICEwt, drICE8K>R,
and drICEK127R were readily ubiquitylated. Mass spectrometric analysis of ubiquitylated
drICE identified at least three ubiquitylated lysines, namely K72, K76, and K142 (Figure
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S6B). Due to limited coverage, no data were obtained on the ubiquitylation status of other
surface-exposed lysine residues.
Importantly, drICE9K>R interacted with DIAP1 as efficiently as drICEwt (Figure 7H),
indicating that the lack of ubiquitylation was not due to impaired DIAP1-binding. Next, we
tested the ability of DIAP1 to regulate drICE9K>R. In the absence of DIAP1, expression of
all drI-CEK>R mutants resulted in their proteolytic activation, as measured by the appearance
of the p10 and DEVDase assays (Figures 7I and S6C). Importantly, proteolytic activation
and activity of all these mutants was comparable to the ones of drICEwt (Figures 7I and
S6C; and data not shown) indicating that the K>R substitutions preserved the overall
caspase structure required for catalytic activity. Coexpression of DIAP121–438 readily
suppressed drICEK>R mutants that lacked up to eight K residues (Figure S6C). In contrast,
drICE9K>R, which lacks all nine surface-exposed K residues, was significantly refractory to
DIAP1-mediated inhibition and efficiently processed its subunits despite the presence of
DIAP121–438 (Figure 7I, compare lanes 2 and 4). Under these conditions, drICE9K>R
retained nearly 70% of its catalytic activity (Figure 7I), while drICEwt was strongly
inhibited, exhibiting merely 5% of its potential activity.
DISCUSSION
Ub-mediated inactivation of caspases has long been postulated to contribute to the
regulation of apoptosis. However, detailed biochemical insights into the actual molecular
and functional consequences of caspase ubiquitylation have not been demonstrated. Here we
provide mechanistic insight into DIAP1’s Ub-dependent ability to inactivate drICE.
Unexpectedly, we find that the covalent attachment of Ub to drICE suppresses its catalytic
potential through a nondegradative mechanism. Although DIAP1 readily promotes
polyubiquitylation of drICE, this does not result in its proteasomal destruction. Several lines
of evidence support the notion that drICE is regulated through polyubiquitylation. First, Ub
conjugation of drICE in vitro significantly reduces its proteolytic activity toward PARP.
Second, drICE9K>R that cannot be ubiquitylated by DIAP1 escapes DIAP1-mediated
inhibition, even though DIAP1 binds to drICE9K>R as efficiently as wild-type drICE.
Finally, DIAP1 point mutations that abrogate its E3 activity toward drICE, or impair its
ability to bind drICE, also fail to suppress drICE in vivo.
The importance of DIAP1’s E3 activity in regulating caspases and cell death is highlighted
by diap1 alleles bearing RING mutations. For DIAP1 to maintain cell viability, it needs to
synchronously neutralize initiator and effector caspases (Kornbluth and White, 2005).
DIAP1 mutations that selectively abrogate binding or ubiquitylation of either initiator or
effector caspases cause loss of DIAP1 function. While DIAP1 targets both DRONC and
drICE for polyubiquitylation and inactivation, the direct consequences of DRONC
ubiquitylation remain to be elucidated (Chai et al., 2003; Wilson et al., 2002). Nevertheless,
it is clear that DIAP1 has to interact with DRONC to regulate it. Surprisingly, we find that
DIAP1’s ability to bind to DRONC depends on DIAP1 cleavage. Removal of DIAP1’s first
20 Aa residues radically changes DIAP1’s properties, as it interacts with DRONC far better
than full-length, noncleaved DIAP1. Thus, full-length DIAP1 seems to reside in an inactive,
“closed” configuration that precludes caspase binding (Yan et al., 2004). Only when it is
cleaved can it bind tightly to DRONC, or effector caspases. In this respect, DIAP1 may
sense caspase activity through caspase-mediated cleavage. Intriguingly, XIAP and cIAP1
reportedly are also cleaved by caspases (Clem, 2001; Deveraux et al., 1999), and it will be
interesting to examine whether such cleavages also alter the functional properties of
mammalian IAPs.
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NH2-terminal cleavage of DIAP1 also substantially changes DIAP1’s E3 activity, as it
exposes a new docking site for UBR-containing E3s. Heteromeric E3 protein complexes are
frequent, as seen in BRCA1/BARD (Brzovic et al., 2001), cIAP1/TRAF2, cIAP2/TRAF2
(Rothe et al., 1995), and MDM2/MDMX (Tanimura et al., 1999). Our observations indicate
that DIAP1 can heterodimerize with several UBR-E3s (Figure 2A) and that its disruption
severely impairs DIAP1’s ability to ubiquitylate drICE (Figure 2E) and regulate apoptosis in
vivo (Figure 3; Ditzel et al., 2003; Tenev et al., 2007). Hence, DIAP1’s two ubiquitylation-
associated activities—UBR-E3 recruitment and DIAP1’s own RING finger—contribute to
its antiapoptotic activity.
Proteins that are ubiquitylated are frequently targeted for proteasomal degradation (Pines
and Lindon, 2005). Thus, one possible scenario is that ubiquitylation inactivates drICE
through proteasomal degradation. While our findings provide a strong link between drICE
ubiquitylation and its activity, we could not detect any Ub-mediated degradation of
ubiquitylated drICE. Several lines of evidence indicate that ubiquitylated drICE is not
degraded. First, inhibition of the proteasome, through treatment with Lactacystin,
cycloheximide, and/or MG132, did not result in any detectable accumulation of
ubiquitylated forms of drICE when compared to untreated controls. Second, the
nonubiquitylatable drICE mutant drICE9K>R displays a comparable protein half-life as its
wild-type counterpart (Figure S7). Third, although coexpression of DIAP1 prevented the
detection of the cleaved, activated form of drICE in immunoblot analysis, this was not due
to its degradation. Inhibition of the proteasome by MG132 did not rescue the appearance of
the p10. Fourth, ectopic expression of DIAP1 in the developing fly eye does not result in the
depletion of drICE. Together, our observations are in agreement with the view that DIAP1-
mediated ubiquitylation of drICE inactivates it through a nondegradative mechanism. Most
likely, the conjugation of Ub to drICE results in steric interference with substrate entry and,
in addition, allosteric conformational impairment of the caspase’s catalytic pocket. In this
respect, ubiquitylation acts as a “mixed” inhibitor displaying both competitive (increased
KM) and noncompetitive (decreased Vmax) inhibitory properties. This notion is consistent
with 3D modeling suggesting that ubiquitylation of several surface-exposed K residues can
occlude substrate entry (Figure S5). Ultimately, crystal structure analysis of ubiquitylated
drICE will be required to validate this model. Allosteric regulation is also seen in caspase-1
(Scheer et al., 2006), indicating that caspases can be regulated through modification of
regulatory residues outside the catalytic pocket.
Although ubiquitylation can affect protein function directly, the most common mode of
regulation by Ub conjugation involves specific “Ub receptors.” This class of protein
recognizes and translates the Ub message into cellular phenotypes (Haglund and Dikic,
2005). Ub receptors carry specialized Ub-binding domains (UBD) through which they
interact with Ub-modified proteins (Haglund and Dikic, 2005). Although Ub conjugation of
active drICE directly suppresses its proteolytic potential, it is likely that, in vivo, Ub-binding
proteins contribute to regulating ubiquitylated caspases, perhaps by spatial sequestration.
Moreover, Ub-binding proteins may also prevent further processing of ubiquitylated and
partially cleaved caspase intermediates. We would like to speculate that Ub conjugation of
caspases might provide cells with a mechanism of restraining the caspase’s proapoptotic
potency, allowing the redeployment of the caspase’s residual catalytic activity toward
nonapoptotic signaling events (Lamkanfi et al., 2007).
Recent studies indicate that healthy cells harbor significant amounts of active caspases
(Ribeiro et al., 2007; Rodriguez et al., 2002). However, little is known about how such cells
establish a buffered threshold of active caspases. Our observations are consistent with a
model (Figures 7J and 7K) in which DIAP1 acts as a “sensor” for the presence of active
effector caspases. While in its full-length form (1), DIAP1 resides in a “closed” inactive
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configuration that precludes caspase binding. DRONC activation via the scaffold protein
DARK (2) (Kornbluth and White, 2005) leads to drICE activation (3) and subsequent
cleavage and activation of DIAP1 (4), which converts it into the caspase-binding competent
E3 that targets caspases for ubiquitylation and inactivation (5). In this respect, caspases
appear to regulate their own inhibition through a negative feedback mechanism that involves
DIAP1. Increasing levels of active caspases would hence lead to DIAP1 “activation” that is
followed by caspase inhibition. DIAP1’s short half-life of 30 min (Wilson et al., 2002; Yoo
et al., 2002) may ensure that once caspase activity levels subside the system returns to the
resting state in which full-length DIAP1 resides in a “closed” inactive configuration. In
effect, such a scenario would result in a buffered “oscillating cycle” of caspase activity that
ensures the continuous presence of sublethal levels of caspase activity (Figure 7J, central
panel).
While the above-mentioned oscillating cycle may operate in living cells, under apoptotic
conditions (Figure 7K) this system is derailed by IAP antagonists (1), or IKKε, that target
DIAP1 for inactivation and/or degradation (Kuranaga et al., 2006; Martin, 2002). Under
such conditions, DIAP1 is eliminated, leading to nonubiquitylated and therefore fully active
caspases (2), cleavage of cellular proteins (3), and apoptosis.
EXPERIMENTAL PROCEDURES
Constructs, Antibodies, and Recombinant Proteins
Constructs were generated by PCR (Easy-A Polymerase, Stratagene); cloned into pAc,
pMT, pMT-GTC (Zachariou et al., 2003), pN-21 (Tenev et al., 2000), or pcDNA3
(Invitrogen); and verified by sequencing. Site-directed mutagenesis was performed using
Pfu Turbo (Stratagene). DHFR-based DIAP1 constructs, full-length DRONC-V5/FLAG,
drICE-V5/FLAG, Ub-ALG-drICEwt or C>A-V5/FLAG, Ub-AKG-DCP-1C>A-V5/FLAG, and
pMT-rpr-FLAG constructs were described previously (Ditzel et al., 2003; Tenev et al.,
2007). DIAP1 was expressed untagged throughout, except for in Figures 2B and 2C, where
DIAP1-GST was used. HA-UBR domains were as follows: UBR159–223 (CG9086),
UBR3174–339 (CG1530), UBR41746–1908 (CG14472), UBR51169–1330 (CG9484),
UBR61040–1182 (CG9461), and UBR71–169 (CG15141). Dm Ub-(CG32744) was cloned into
His/HA-pAC. Constructs for transgenesis: the dhfr-diap1 coding region was cloned into
pKB (Basler and Struhl, 1994) containing the tubulin promoter. The tubulin-promoter-dhfr-
diap1 was subcloned into pop-118 (Basler and Struhl, 1994). For the generation of
recombinant proteins, the coding regions of drICE, DIAP1, DIAP1F437A, and Effete (Dm
UbcD1) were cloned into pGEX6p1 (GE-Healthcare) and purified from bacteria as
previously described (Zachariou et al., 2003). GST tags were removed by PreScission
cleavage (GE-Healthcare). Recombinant Ub and E1 were a gift from D. Komander (ICR,
London). The following antibodies were used: α-V5 (AbD Serotec), α-GST (GE
Healthcare), a-HA (Roche), a-PARP1 (Santa Cruz), α-Ub (FK2, Biomol), mouse- and rat-
derived secondary HRP-conjugated antibodies (Santa Cruz), and guinea pig-derived
secondary HRP-conjugated antibody (Rockland). α-DIAP1 and α-drICE antibodies were
described previously (Zachariou et al., 2003).
LI-COR Odyssey Analysis
To quantitate expression levels, immunoblots were incubated with the indicated Odyssey-
compatible secondary antibodies (mouse IR680 (Invitrogen), rat IR680 (Invitrogen), and
guinea pig IR800 (Rockland) and analyzed at 700 nm excitation. Odyssey software was used
to determine the integrated intensities.
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Fly Stocks
GMR-rpr was described previously (Wilson et al., 2002). pop118-based transgenic lines
expressing tubulin-driven DIAP1-wt, -D20A, -C406Y, and -D20A/C406Y; N-DIAP121–438, -C406Y;
and M-DIAP121–438 were generated by Bestgene, USA. Crosses were performed at 25°C
throughout. Images of adult heads were acquired using a stereo microscope (Leica) equipped
with a Plan Apo 1.0× lens, a digital camera (Nikon), and image capture software (Nikon).
Selection of transgenic lines expressing equivalent reference proteins: ten heterozygous
female flies were lysed in boiling 1 × SDS sample buffer and analyzed by western blot to
detect V5-DHFR expression. To induce DIAP1-overexpressing clones, males of hs-
flp;tub>GFP>Gal4 genotype (provided by H.D. Ryoo; > denotes FRT) were crossed to
UAS-diap1 females (provided by B. Hay). Clones were induced by 1 hr heat shock at 37°C
during first-instar larval stage. third-instar larval eye discs were dissected and labeled with
anti-drICE antibody.
DEVDase Assays and drICE Western Analysis
S2 and HEK293T cells were cultured and transfected as described previously (Tenev et al.,
2005). For the cell-based DEVDase assays in S2 cells, expression of Rpr (pMT-rpr) or
drICE (pMT-drice) was induced with 350 μM CuSO4 for 4 or 6 hr. Cells were lysed as
described previously (Tenev et al., 2005), and 20 μl of cleared supernatant was added to 350
μl of DEVDase assay mix (20 μM DEVD-AMC (Calbiochem), 2 mM DTT, 10 mM Tris
(pH 7.5), 150 mM NaCl, 0.1% TX-100, and 5% glycerol). The reaction was incubated at RT
for 10 min and analyzed at 380 nM excitation/460 nM emission. Extract from the same
lysates were also analyzed for drICE by immunoblot analysis. For Figure 5B, cells were
treated as above with DMSO, 40 μM z-VAD (BioMol), 50 μM MG132 (Sigma), or a
combination of z-VAD and MG132. For Figure S7, 6 hr after drICE induction, S2 cells were
treated with 40 μM z-VAD and lysed at the indicated time points post-z-VAD-addition.
Immunoprecipitation and Immunoblot Analysis
Coimmunoprecipitation and immunoblot assays were performed as described previously
(Tenev et al., 2005). For Figure 1E, GTC-tagged Reaper was expressed in S2 cells, bound to
GSH-Sepharose, and incubated with DIAP1-containing lysates from transfected 293T cells.
For Figure 2G, S2 cells were left untreated or irradiated with 150K μJ UV (UV Stratalinker,
Stratagene) and lysed after 4 hr in lysis buffer containing 50 mM Chloroacetamide.
Endogenous drICE was immunoprecipitated using guinea-pig-derived α-drICE antibody and
the Seize-X Protein A Immunoprecipitation Kit (Pierce). To detect ubiquitylated drICE, the
membrane was incubated for 1 hr in 6 M GuHCl, 20 mM Tris (pH 7.5), 1 mM PMSF, and 5
mM β-ME at 4°C.
Ubiquitylation Assays
Cells were cotransfected with the indicated constructs at equal ratios. For Figures 5A and
S3, cells were incubated for 6 hr with 10 μM Lactacystin (Calbiochem), 50 μg/ml
cycloheximide (Sigma), and/or 50 μM MG132 (Sigma) prior to lysis. After 48 hr, cells were
harvested and lysed under denaturing conditions, and ubiquitylated proteins were purified
using Ni2+-NTA agarose beads (QIAGEN) as described previously (Rodriguez et al., 1999).
In Vitro Ubiquitylation and PARP Cleavage Assay
Active drICE (4 μg) was incubated in the presence or absence of 1 μg DIAP1, 1 μg
DmUbcD1, 80 ng E1, and 2 μg Ub in a final volume of 30 μl reaction buffer (2 mM ATP,
40 mM Tris-HCl [pH 7.5], 10 mM MgCl2, 0.6 mM DTT). Reactions were carried out at
37°C for 90 min. For immunoblot analysis, 15 μl of the total reaction was used, while the
remaining 15 μl were tested for drICE activity on PARP. For PARP cleavage assays, 1.2 μg
Ditzel et al. Page 10
Mol Cell. Author manuscript; available in PMC 2009 November 21.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
of recombinant PARP (R&D Systems) was added to the drICE ubiquitylation reactions and
incubated for a further 25 min at 37°C. Samples were analyzed by immunoblot analysis and
quantified using the LI-COR Odyssey technology.
Enzyme Kinetics
Experiments for determining KM and Vmax were performed in triplicates and analyzed with
Prism software. Results of the independent DEVDase assay were standardized to the values
obtained for 40 μM substrate of ubiquitylated drICE.
Modeling of drICE
The 3D structure of drICE was modeled using the X-ray structure of human caspase-7 (PDB
code 1I4O) as a template. Note, drICE is 40% identical to caspase-7. An initial model of
drICE was built using MolIDE (Canutescu and Dunbrack, 2005). The model was refined
using QuantaTM and subjected to dynamics and minimization using YASARA (Krieger et
al., 2002).
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. DIAP1 Cleavage Enhances Caspase Binding
(A) Model depicting DIAP1’s hypothetical “closed” and “open” configuration. A vertical
arrow marks the site of caspase cleavage.
(B–E) Coimmunoprecipitation (IP) assays with the indicated constructs. Lysates and V5
immunoprecipitates were analyzed by immunoblotting with the indicated antibodies. The
two arrows on the DIAP1 panels indicate the positions of full-length and cleaved DIAP1.
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Figure 2. Cleaved DIAP1 Binds to UBR Domains and Promotes Ubiquitylation of drICE and
DCP-1
(A) Schematic representation of caspase-mediated DIAP1 cleavage, maturation, and UBR
binding. See text for details.
(B) Co-IP assays with DIAP121–438 and various UBR domains. S2 cells were cotransfected
with GTC-tagged DIAP121–438 and HA-tagged UBR domains of the indicated UBR
proteins. Copurified proteins were analyzed by immunoblotting with the indicated
antibodies.
(C) Co-IPs were performed as in (B) with N-, RD-, and M-DIAP121–438 and the UBR
domain of UBR1.
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(D and E) Requirement of DIAP1’s RING domain and N-exposure in mediating effector
caspase ubiquitylation. 293T (D) or S2 (E) cells were cotransfected with the indicated
DIAP1 constructs together with Ub-AKG-DCP-1C>A (D) or Ub-ALG-drICEC>A (E) and
His-Ub. Cells were lysed under denaturing conditions and ubiquitylated proteins isolated
with Ni2+ columns. The presence of ubiquitylated caspases was identified by
immunoblotting with the indicated antibodies.
(F) DIAP1 and drICE bind through a bimodular interaction. Mutation of the IBM weakens
but does not abrogate DIAP1 binding. Ubiquitylation assays with the indicated constructs
were performed as in (D).
Asterisks mark a nonspecific band ([D] and [F]) and unmodified drICE (E) that is due to a
nonspecific drICE:matrix association.
(G) Endogenous drICE is ubiquitylated in a DIAP1-dependent manner. S2 cells were either
left untreated or exposed to UV, and α-drICE or preimmune serum was used to
immunoprecipitate drICE from cellular extracts. The presence of ubiquitylated endogenous
drICE was determined by immunoblotting with an α-Ub antibody (top panel). Note,
treatment with UV causes depletion of DIAP1 (bottom panel, lane 3).
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Figure 3. DIAP1 Requires Cleavage and a Functional RING to Suppress Apoptosis In Vivo
(A) Overview of the Ub fusion technique. Tubulin-driven DIAP1 variants were expressed as
V5-DHFR/Ub-DIAP1 fusion in which the reference protein DHFR/Ub is cotranslationally
cleaved off by DUBs. Expression of the reference protein indirectly indicates the expression
level of the protein of interest. DIAP1’s NH2-terminal sequence and the caspase cleavage
site (DQVD, arrowhead) are indicated.
(B) Selection of transgenic lines with “near” equivalent expression levels of the reference
protein (upper panel). Quantitative, infrared fluorescence-based measurement of V5-DHFR-
Ub expression levels (lower panel).
(C–J) The ability of DIAP1 to suppress the eye phenotypes of Rpr expression. Rpr
expression results in a small-eye phenotype (C) that is rescued by tubulin-driven
coexpression of DIAP1wt (D) and N-DIAP121–438 (F), but not DIAP1D20A (E), M-
DIAP121–438 (G), or RING mutants (H–J). Representative phenotypes are shown.
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Figure 4. DIAP1-Mediated Ubiquitylation of drICE Correlates with Its Inactivation
(A) The E3 ligase activity of DIAP1 is required to suppress effector caspase activity induced
by Rpr. S2 cells were cotransfected with the indicated constructs, and cell lysates were
assayed for DEVDase activity. Values of Rpr-expressing controls were set to 100% (lanes 2
and 8). Immunoblot analysis of the lysates indicates near-equivalent expression levels of the
DHFR reference protein (upper panels).
(B) RING-dependent ubiquitylation of drICE. Ubiquitylation assays were performed as in
Figure 2E. Asterisks represent nonspecific bands.
(C) DIAP1’s E3 activity is required to suppress appearance of processed drICE (p10) and
DEVDase activity. Schematic representation of cleavage-mediated activation of drICE
(upper panel). Arrows indicate cleavage sites. DIAP1 coexpression, but not the indicated
range of ubiquitylation-deficient DIAP1 mutants, efficiently prevents detection of drICE’s
small subunit. S2 cells were cotransfected with the indicated constructs. Following a 6 hr
induction of drICE, cell lysates were simultaneously analyzed for DEVDase activity and by
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immunoblotting with the indicated antibodies. Values were normalized to drICE in vector
controls (lane 2). DEVDase values and immunoblot analysis of a representative experiment
are shown.
(D) M-DIAP121–438 is less efficient than N-DIAP121–438 in suppressing drICE activation
and activity, as indicated by the presence of the p10 subunit of drICE and significant
amounts of DEVDase activity. Experiments were performed as in (C). DEVDase values and
immunoblot analysis of a representative experiment are shown. Error bars denote SD from
three independent experiments.
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Figure 5. Ubiquitylation of drICE Suppresses Its Catalytic Potential
(A) Inhibition of the proteasome does not alter the ubiquitylation pattern of drICE. 293T
cells were cotransfected with the indicated constructs and treated with Lactacystin or DMSO
(control). The presence of ubiquitylated drICE was assayed as in Figure 2E.
(B) Proteasome inhibition failed to restore the appearance of the small subunit of drICE. S2
cells were cotransfected with the indicated constructs. Following a 2 hr drICE induction,
cells were treated for a further 4 hr with MG132 or DMSO.
(C) Clonal expression of DIAP1 in the developing eye does not reduce the levels of drICE.
Eye discs overexpressing DIAP1 in clones (marked by the absence of GFP, first and last
panel) were stained using an α-drICE antibody (red, middle panel).
(D) S2 cells were cotransfected with the indicated constructs. Immunoblot analysis (left
panel) revealed that zymogenic ALG-drICE accumulated at the expense of processed drICE
(p10) in the presence of DIAP1. LI-COR Odyssey quantification (right panel) of the drICE
signal.
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Figure 6. Conjugation of Ub to drICE Acts as a “Mixed” Inhibitor
(A) In vitro ubiquitylation of recombinant drICE suppresses its catalytic ability to cleave
PARP. Schematic representation of the assay procedure (left panels). In vitro ubiquitylation
assay of active drICE with DIAP1 or DIAP1F437A. Arrows on the DIAP1 panel indicate
DIAP1 cleavage. (Bottom panel) Step 2 depicting in vitro PARP cleavage assay: the
ubiquitylation reactions from step 1 were incubated with recombinant PARP. Shown is
immunoblot analysis with α-PARP antibodies. Graphs indicate LI-COR Odyssey
quantification of the signal expressed as % of processed PARP in relation to total PARP
(lower panel). Values and immunoblot analysis of a representative experiment are shown.
(B and C) Ubiquitylation changes kinetic parameters of active drICE. drICE was incubated
in an in vitro ubiquitylation reaction with DIAP1 or DIAPF437A as in Figure 5D. (B) 10.3
nmole of PARP (left panel, a representative experiment is shown) or increasing
concentrations of PARP (2.1–34.5 nmole, 15 min, right panel) was incubated with drICE or
ubiquitylated drICE. PARP cleavage was monitored by immunoblot analysis. Western blot
data were analyzed by LI-COR Odyssey quantification as in Figure 5D. Nonlinear
regression using the Michaelis-Menten equation was applied to obtain a curve fit (right
panel). (C) drICE was incubated in an in vitro ubiquitylation reaction with DIAP1 or
DIAPF437A as in Figure 5D. drICE and ubiquitylated drICE were incubated with 20 μM
DEVD-AMC, and DEVDase activity was analyzed at the indicated time points (left panel,
shown is a representative experiment). (Right panel) Increasing substrate concentrations
were used, and DEVDase activity was measured at 20 min. Curve fit was performed as in
(B). RFU, relative fluorescence units.
(D) KM and Vmax (±SE) were determined from the curves shown in (B) and (C) using Prism
software.
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Figure 7. Nonubiquitylatable drICE Is Refractory to DIAP1-Mediated Inhibition
(A) Schematic representation showing the position of surface-exposed K residues in the
large subunit.
(B–E) 3D model of drICE dimers. drICE monomers are colored in blue and gray, and
surface-exposed K residues are highlighted in red. Residues involved in catalysis are
highlighted in yellow. Four different viewpoints of drICE are shown.
(F) K>R mutation schedule. Additive rounds of K>R mutations were carried out, and their
effects on DIAP1-mediated regulation of drICE were assessed in cell-based DEVDase
assays (as in Figure 4C). “++++” reflects no change and “−” reflects loss of DIAP1-
mediated inhibition of drICE.
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(G) drICE9K>R is refractory to DIAP1-mediated ubiquitylation. S2 cells were cotransfected
with DIAP121–438, His-Ub, and the indicated drICE-V5/FLAG constructs, and cell lysates
were analyzed for the presence of ubiquitylated caspases.
(H) drICE9K>R readily binds to DIAP1. Experiment performed as in Figure 1D.
(I) drICE9K>R is refractory to DIAP1-mediated inhibition. drICE9K>R was examined as in
Figure S6C. The mean values of triplicate experiments and their SD are shown. Immunoblot
analysis of a representative experiment is shown.
(J and K) Model of caspase regulation in living (J) and dying cells (K). See Discussion for
details.
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